[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100572916":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":17,"locations":7,"responsibleParty":25,"collaborators":7,"id":28,"slug":29,"hasResults":30,"nctId":31,"briefTitle":32,"officialTitle":32,"acronym":7,"eligibilityCriteria":33,"healthyVolunteers":30,"sex":34,"minAge":35,"maxAge":36,"enrollmentInfo":37,"targetDuration":7,"studyType":40,"phases":7,"briefSummary":41,"conditions":42,"keywords":47,"overallStatus":54,"whyStopped":7,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":7},{"fullName":5,"class":6},"Assiut University","OTHER",null,[9,12,15],{"name":10,"affiliation":5,"role":11},"Abdallah A Gamal, Resident","PRINCIPAL_INVESTIGATOR",{"name":13,"affiliation":5,"role":14},"Lobna A Farag, Lecturer","STUDY_DIRECTOR",{"name":16,"affiliation":5,"role":14},"Mohamed A Abozaid, Lecturer",[18,22],{"name":10,"role":19,"phone":20,"phoneExt":7,"email":21},"CONTACT","01153381807","drboudy81@gmail.com",{"name":13,"role":19,"phone":23,"phoneExt":7,"email":24},"01005571004","leltoni@yahoo.com",{"type":11,"investigatorFullName":26,"investigatorTitle":27,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Abdallah Gamal Eldin Shawky Mohamed Hamad","Internal resident","100572916","efficacy-of-sodium-glucose-cotransporter-2-inhibitors-on-non-alcoholic-fatty-liver-disease-100572916",false,"NCT06739486","Efficacy of Sodium Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease","Inclusion Criteria:\n\n* age \\>18 years\n* both sex\n\nExclusion Criteria:\n\n* alcohol drinker\n* any cause of liver affection (hepatitis, autoimmune…etc)\n* patients with kidney function affection","ALL","18 Years","65 Years",{"count":38,"type":39},100,"ESTIMATED","OBSERVATIONAL","evaluate the effectiveness of sodium-glucose cotransporter-2 (SGLT.2) inhibitors in improving hepatic steatosis and hepatic fibrosis using imaging biomarkers and histopathology in patients with non-alcoholic fatty liver disease",[43,44,45,46],"Non Alcholic Fatty Liver Disease","Hepatic Steatosis","Hepatic Fibrosis","NAFLD (Nonalcoholic Fatty Liver Disease)",[48,49,50,51,52,53],"NAFLD","Non alcoholic fatty liver disease","Hepatic steatosis","Hepatic fibrosis","Na glucose cotransporter 2 inhibitors","SGLT-2 inhibitors","NOT_YET_RECRUITING","2024-12-17",{"date":57,"type":58},"2024-12-18","ACTUAL",{"date":60,"type":39},"2024-12-20",{"date":62,"type":39},"2025-12-20",{"name":5,"class":6}]